The PARTNER trial of neoadjuvant olaparib with chemotherapy in triple-negative breast cancer.
Jean E Abraham, Karen Pinilla, Alimu Dayimu, Louise Grybowicz, Nikolaos Demiris, Caron Harvey, Lynsey M Drewett, Rebecca Lucey, Alexander Fulton, Anne N Roberts, Joanna R Worley, Anita Chhabra, Wendi Qian, Anne-Laure Vallier, Richard M Hardy, Steve Chan, Tamas Hickish, Devashish Tripathi, Ramachandran Venkitaraman, Mojca Persic, Shahzeena Aslam, Daniel Glassman, Sanjay Raj, Annabel Borley, Jeremy P Braybrooke, Stephanie Sutherland, Emma Staples, Lucy C Scott, Mark Davies, Cheryl A Palmer, Margaret Moody, Mark J Churn, Jacqueline C Newby, Mukesh B Mukesh, Amitabha Chakrabarti, Rebecca R Roylance, Philip C Schouten, Nicola C Levitt, Karen McAdam, Anne C Armstrong, Ellen R Copson, Emma McMurtry, Marc Tischkowitz, Elena Provenzano, Helena M Earl
Nature 629(8014) 1142-1148
摘要
摘要
PARTNER is a prospective, phase II-III, randomized controlled clinical trial that recruited patients with triple-negative breast cancer1,2, who were germline BRCA1 and BRCA2 wild type3. Here we report the results of the trial. Patients (n = 559) were randomized on a 1:1 basis to receive neoadjuvant carboplatin-paclitaxel with or without 150 mg olaparib twice daily, on days 3 to 14, of each of four cycles (gap schedule olaparib, research arm) followed by three cycles of anthracycline-based chemotherapy before surgery. The primary end point was pathologic complete response (pCR)4, and secondary end points included event-free survival (EFS) and overall survival (OS)5. pCR was achieved in 51% of patients in the research arm and 52% in the control arm (P = 0.753). Estimated EFS at 36 months in the research and control arms was 80% and 79% (log-rank P > 0.9), respectively; OS was 90% and 87.2% (log-rank P = 0.8), respectively. In patients with pCR, estimated EFS at 36 months was 90%, and in those with non-pCR it was 70% (log-rank P < 0.001), and OS was 96% and 83% (log-rank P < 0.001), respectively. Neoadjuvant olaparib did not improve pCR rates, EFS or OS when added to carboplatin-paclitaxel and anthracycline-based chemotherapy in patients with triple-negative breast cancer who were germline BRCA1 and BRCA2 wild type. ClinicalTrials.gov ID: NCT03150576 .
KM 提取结果
0 个 Figure · 0 个 KM 面板